A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Fulvestrant|DRUG: BKM120|DRUG: BKM120 matching placebo
Sponsor: Novartis Pharmaceuticals